Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2000 3
2001 2
2002 5
2003 4
2004 4
2005 5
2006 3
2007 3
2008 1
2009 3
2010 1
2011 2
2012 9
2013 12
2014 9
2015 9
2016 2
2017 4
2018 4
2020 1
2021 2
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 15598954

85 results

Results by year

Filters applied: . Clear all
Page 1
Phase II study of E7070 in patients with metastatic melanoma.
Smyth JF, Aamdal S, Awada A, Dittrich C, Caponigro F, Schöffski P, Gore M, Lesimple T, Djurasinovic N, Baron B, Ravic M, Fumoleau P, Punt CJ; EORTC New Drug Development and Melanoma Groups. Smyth JF, et al. Ann Oncol. 2005 Jan;16(1):158-61. doi: 10.1093/annonc/mdi016. Ann Oncol. 2005. PMID: 15598954 Free article. Clinical Trial.
Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours. A study by the EORTC Early Clinical Study Group (ECSG).
Terret C, Zanetta S, Roché H, Schellens JH, Faber MN, Wanders J, Ravic M, Droz JP; EORTC Early Clinical Study Group. Terret C, et al. Eur J Cancer. 2003 May;39(8):1097-104. doi: 10.1016/s0959-8049(03)00128-x. Eur J Cancer. 2003. PMID: 12736109 Clinical Trial.
A phase II clinical and pharmacodynamic study of E7070 in patients with metastatic, recurrent, or refractory squamous cell carcinoma of the head and neck: modulation of retinoblastoma protein phosphorylation by a novel chloroindolyl sulfonamide cell cycle inhibitor.
Haddad RI, Weinstein LJ, Wieczorek TJ, Bhattacharya N, Raftopoulos H, Oster MW, Zhang X, Latham VM Jr, Costello R, Faucher J, DeRosa C, Yule M, Miller LP, Loda M, Posner MR, Shapiro GI. Haddad RI, et al. Clin Cancer Res. 2004 Jul 15;10(14):4680-7. doi: 10.1158/1078-0432.CCR-04-0229. Clin Cancer Res. 2004. PMID: 15269140 Clinical Trial.
Vitiligo in 2 patients receiving vemurafenib for metastatic melanoma.
Alonso-Castro L, Ríos-Buceta L, Vano-Galvan S, Moreno C, Soria-Rivas A, Jaén P. Alonso-Castro L, et al. J Am Acad Dermatol. 2013 Jul;69(1):e28-9. doi: 10.1016/j.jaad.2013.01.012. J Am Acad Dermatol. 2013. PMID: 23768302 No abstract available.
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ, Amonkar MM, Karaszewska B, Schachter J, Dummer R, Mackiewicz A, Stroyakovskiy D, Drucis K, Grange F, Chiarion-Sileni V, Rutkowski P, Lichinitser M, Levchenko E, Wolter P, Hauschild A, Long GV, Nathan P, Ribas A, Flaherty K, Sun P, Legos JJ, McDowell DO, Mookerjee B, Schadendorf D, Robert C. Grob JJ, et al. Lancet Oncol. 2015 Oct;16(13):1389-98. doi: 10.1016/S1470-2045(15)00087-X. Lancet Oncol. 2015. PMID: 26433819 Clinical Trial.
A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma.
Hamid O, Ilaria R Jr, Garbe C, Wolter P, Maio M, Hutson TE, Arance A, Lorigan P, Lee J, Hauschild A, Mohr P, Hahka-Kemppinen M, Kaiser C, Turner PK, Conti I, Grob JJ. Hamid O, et al. Cancer. 2014 Jul 1;120(13):2016-24. doi: 10.1002/cncr.28635. Epub 2014 Mar 26. Cancer. 2014. PMID: 24676877 Free article. Clinical Trial.
85 results